• Company
• Dupixent seeks to expand its indication to COPD
• by Eo, Yun-Ho Dec 18, 2023 05:31am

• Policy
• PVA price cut rate will be raised by up to 15%
• by Lee, Tak-Sun Dec 18, 2023 05:31am

• Opinion
• [Reporter’s view] On improving self-sufficiency of APIs
• by Kim, Jin-Gu Dec 18, 2023 05:31am

• Reimb discussion on Braftovi and Luxturna continue next year
• by Eo, Yun-Ho Dec 18, 2023 05:31am

• Company
• SK pneumococcal conjugate vaccine nears global entry
• by Chon, Seung-Hyun Dec 15, 2023 05:51am

• Policy
• Global orphan drug Lamzede receives GIFT designation
• by Lee, Hye-Kyung Dec 15, 2023 05:51am

• Policy
• HER2-positive metastatic breast cancer drug Tukysa approved
• by Lee, Hye-Kyung Dec 15, 2023 05:51am

• Company
• Reimb for Cold Agglutinin Disease drug Enjaymo starts in KOR
• by Eo, Yun-Ho Dec 15, 2023 05:51am

• Company
• US-expanded Cresemba faces reimb challenges in KOR
• by Son, Hyung-Min Dec 15, 2023 05:51am

• Policy
• Non-inferior drugs likely to receive preferential pricing
• by Lee, Tak-Sun Dec 15, 2023 05:51am